^
BIOMARKER:

KMT2C mutation

i
Other names: MLL3, KMT2C, Lysine Methyltransferase 2C, Histone-Lysine N-Methyltransferase 2C, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 3, Lysine (K)-Specific Methyltransferase 2C, Histone-Lysine N-Methyltransferase, H3 Lysine-4 Specific, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 3, Histone-Lysine N-Methyltransferase MLL3, Lysine N-Methyltransferase 2C, ALR-Like Protein, KLEFS2
Entrez ID:
Related biomarkers:
KMT2C mutation
CRC
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
Solid Tumor
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
CRC
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
HCC
PD1 inhibitor + lenvatinib
Sensitive: C3 – Early Trials
KMT2C mutation
RCC
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
KMT2C mutation
Bladder Cancer
Immunotherapy
Sensitive: C3 – Early Trials